Rebecca B. Robertson Sells 20,000 Shares of CeriBell, Inc. (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Rebecca B. Robertson sold 20,000 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $17.14, for a total value of $342,800.00. Following the completion of the sale, the director now directly owns 28,675 shares of the company's stock, valued at approximately $491,489.50. This trade represents a 41.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

CeriBell Stock Up 0.6%

NASDAQ:CBLL traded up $0.11 during mid-day trading on Friday, reaching $17.91. The stock had a trading volume of 254,336 shares, compared to its average volume of 282,197. The business's 50 day moving average is $16.61 and its 200 day moving average is $20.83. The company has a current ratio of 17.36, a quick ratio of 16.81 and a debt-to-equity ratio of 0.11. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. The business had revenue of $20.49 million for the quarter, compared to analyst estimates of $19.30 million. As a group, equities research analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Several institutional investors have recently bought and sold shares of CBLL. FMR LLC bought a new stake in shares of CeriBell during the 4th quarter worth about $128,120,000. TPG GP A LLC bought a new stake in CeriBell in the 4th quarter valued at $102,677,000. Red Tree Management LLC acquired a new position in CeriBell in the fourth quarter worth about $57,083,000. Yu Fan acquired a new position in shares of CeriBell in the 4th quarter worth approximately $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd bought a new position in shares of CeriBell during the fourth quarter valued at $28,160,000.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. LADENBURG THALM/SH SH began coverage on CeriBell in a research note on Friday, April 4th. They set a "buy" rating and a $32.00 target price on the stock. Canaccord Genuity Group restated a "buy" rating and set a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $32.50.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.